These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28520581)

  • 1. Reply to: Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Dominguez-Munoz JE
    J Clin Gastroenterol; 2019 Apr; 53(4):315-316. PubMed ID: 28520581
    [No Abstract]   [Full Text] [Related]  

  • 2. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients.
    Dai C; Cao Q; Jiang M
    J Clin Gastroenterol; 2019 Apr; 53(4):314. PubMed ID: 28157734
    [No Abstract]   [Full Text] [Related]  

  • 3. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2018 Mar; 52(3):229-234. PubMed ID: 27984399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Calprotectin as a Predictor of Relapse in Patients With Inflammatory Bowel Disease.
    Dai C; Jiang M; Sun MJ
    J Clin Gastroenterol; 2015 Sep; 49(8):715. PubMed ID: 25984977
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Oct; 44(7):770-1. PubMed ID: 27593429
    [No Abstract]   [Full Text] [Related]  

  • 7. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
    Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
    Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease.
    Yamamoto T; Shimoyama T; Kuriyama M
    Aliment Pharmacol Ther; 2016 Oct; 44(7):769-70. PubMed ID: 27593428
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
    van Rheenen PF
    Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.